Vernakalant

Chemical formula: C₂₀H₃₁NO₄ Molecular mass: 349.471 g/mol PubChem compound: 9930049

Therapeutic indications

Vernakalant is indicated for:

Atrial fibrillation

Population group: only adults (18 - 65 years old)

Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults:

For non-surgery patients: atrial fibrillation ≤7 days duration.
For post-cardiac surgery patients: atrial fibrillation ≤3 days duration.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

3 mg/kg

Contraindications

Vernakalant is contraindicated in the following cases:

Prolonged QT, severe bradycardia, sinus node dysfunction, second degree and third degree heart block

at least one of

Prolonged QT interval
Long QT syndrome
Bradycardia
Coronary sinus rhythm disorder
Second degree atrioventricular block
Complete atrioventricular block

Acute coronary syndrome

Acute ischemic heart disease

Class I antiarrhythmics, class III antiarrhythmics

Antiarrhythmics, class I and III

Severe aortic stenosis, heart failure class NYHA III and NYHA IV

at least one of

Severe stenosis of aortic valve
Heart failure New York Heart Assosiation Class IΙΙ
Heart failure New York Heart Assosiation Class IV

Hypotension

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.